Markets

Strength Seen in Receptos, Inc. (RCPT) as Stock Shoots up 36.78% - Tale of the Tape

Receptos, Inc. ( RCPT ) was a big mover last session, as the company saw its shares surge a whopping 37% on the day. This tremendous rally can be attributable to solid volume too with far more shares changing hands than in a normal session. This broke the recent trend of the company, as the stock is now trading above the volatile price range of $24.99 to $30.43 in the past one-month time frame.

The company has seen 2 negative revisions in the past 1 month, while its Zacks Consensus Estimate of a loss widened over the same period, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent move higher can last.

Receptos currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.

Other attractive players in the healthcare industry include Illumina Inc. ( ILMN ) and Gilead Sciences Inc. ( GILD ), carrying a Zacks Rank #1 (Strong Buy) and Ariad Pharmaceuticals Inc. ( ARIA ) with a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

RECEPTOS INC (RCPT): Free Stock Analysis Report

ILLUMINA INC (ILMN): Free Stock Analysis Report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

ARIAD PHARMA (ARIA): Free Stock Analysis Report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GILD ILMN

Other Topics

Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More